参附注射液治疗恶性肿瘤化疗相关性血小板减少的效果及安全性

Safety and efficacy of Shenfu injection in treatment of malignant tumor chemotherapy associated thrombocytopenia

目的观察参附注射液治疗恶性肿瘤化疗相关性血小板减少的临床效果及安全性。方法选取常规化疗2个周期的恶性肿瘤患者40例为观察组,均在化疗前2~3d接受参附注射液治疗,另外选择同期化疗的未接受参附注射液治疗的恶性肿瘤患者40例为对照组,比较2组血小板下降值及不良反应发生情况。结果随着时间延长,2组血小板值均呈下降趋势,观察组下降幅度小于对照组（P〈0.01）。观察组不良反应发生率为25.0%,明显低于对照组的67.5%（P〈0.01）。结论参附注射液能有效抑制恶性肿瘤化疗后血小板下降,减少不良反应发生率,疗效可靠,安全性高,可在恶性肿瘤化疗中推广使用。

Objective To study the clinical efficacy and safety of Shenfu injection in treatment of malignant tumor chemotherapy associated thrombocytopenia.Methods Forty with malignant tumor, patients prepared for two cycles of chemotherapy were treated by Shenfu injection 2--3 d before chemotherapy as obsenation group,at the same period,40 malignant tumor with chemotherapy patients without shenfu injection served as control group. Two groups of patients were compared in thrombocytopenia and adverse reaction.Results With time extending, two groups of patients showed decrease in thrombocyte values, and observation group decreased significantly less than control group（P〈0.01）.The adverse reactions in observation group was 25.0% ,which was significantly lower than that in control group,67.5% （P〈0.01）.Conclusion Shenfu injection can effectively inhibit the decrease of platelet in the patients after chemotherapy, reduce the rate of adverse symptoms,and Shenfu injection has reliable efficacy and high safety,it could be widely used in the treatment of malignant tumor with chemotherapy.